The Prognostic Value of Pre-Treatment Leukocytosis in Patients with Previously Treated, Stage IIIB/IV Non-Small Cell Lung Cancer Treated with the IGF-1R Pathway Modulator AXL1717 or Docetaxel; a Retrospective Analysis of a Phase II Trial

BACKGROUND: The aim of the present study was to investigate any prognostic value of pre-treatment anemia, leukocytosis and thrombocytosis in patients with advanced pretreated NSCLC. METHODS: A randomized, multicenter phase II study comparing the IGF-1R modulator AXL with standard docetaxel in the tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Holgersson, Georg, Bergqvist, Michael, Nilsson, Jonas, Thureson, Marcus, Harmenberg, Johan, Bergstrom, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373797/
https://www.ncbi.nlm.nih.gov/pubmed/28669167
http://dx.doi.org/10.22034/APJCP.2017.18.6.1555

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373797/
https://www.ncbi.nlm.nih.gov/pubmed/28669167
http://dx.doi.org/10.22034/APJCP.2017.18.6.1555

Ejemplares similares